血浆miRNA-126表达与妊娠期高血压疾病的相关性分析

Abstract
Figure/Table
References (24)
Related Citation (9)

Download: PDF (612 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the relationship between the expression of plasma miRNA-126 and hypertensive disorder complicating pregnancy. Methods A total of 93 patients with hypertensive disorder complicating pregnancy admitted in Luzhou People′s Hospital of Sichuan Province from February 2015 to February 2018 were selected as the study subjects and grouped according to their diseases. There were 30 cases in pregnancy hypertension group, 29 cases in mild preeclampsia group and 34 cases in severe preeclampsia group. Another 20 healthy pregnant women who underwent physical examination during the same period were taken as control group. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expression of plasma miRNA-126 of each group, and the levels of systolic blood pressure, diastolic blood pressure and 24-hour proteinuria level were compared, and the correlation between them and the expression of plasma miRNA-126 were analyzed. Results Compared with the control group, the expression of plasma miRNA-126 was down-regulated in the pregnancy hypertension group, while the expression of plasma miRNA-126 in the mild preeclampsia group was lower than that in the pregnancy hypertension group, and the miRNA-126 expression in the severe preeclampsia group was lower than that in the mild preeclampsia group, the difference were statistically significant (P < 0.05). The systolic blood pressure and 24-hour proteinuria level in pregnancy hypertension group were significantly higher than those in control group; the systolic blood pressure and 24-hour proteinuria level in mild preeclampsia group were higher than those in pregnancy hypertension group; the systolic blood pressure and 24-hour proteinuria level in severe preeclampsia group were higher than those in mild preeclampsia group; the diastolic blood pressure levels in control group were lower than those in pregnancy hypertension group, mild preeclampsia group, severe preeclampsia group, the differences were statistically significant (all P < 0.05). According to Spearman correlation analysis, the expression of miRNA-126 gene in patients with hypertensive disorder complicating pregnancy was negatively correlated with systolic blood pressure, diastolic blood pressure and 24-hour proteinuria level (r = -0.583, -0.626, -0.611, P < 0.05). Conclusion The expression of plasma microRNA-126 in patients with hypertensive disorder complicating pregnancy is significantly down-regulated, and with the aggravation of the disease, the expression of plasma miRNA-126 is down-regulated more obviously. The down-regulation of the expression of plasma miRNA-126 may play an important role in the occurrence and development of hypertensive disorder complicating pregnancy.

Key words： Hypertensive disorder complicating pregnancy miRNA-126 Plasma Mild preeclampsia Severe preeclampsia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Xiaoyan1 PENG Shihan1 ZHAO Lei1 LUO Yuping1 LIU Xia2

Cite this article:

HE Xiaoyan1 PENG Shihan1 ZHAO Lei1 LUO Yuping1 LIU Xia2. Correlation analysis of the expression of plasma miRNA-126 and hypertensive disorder complicating pregnancy[J]. 中国医药导报, 2019, 16(8): 76-79.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I8/76

[1] 单莉莉，韩涛，安娜，等.Lp-PLA2与妊娠期高血压疾病关系及其临床意义[J].临床军医杂志，2017，45（2）：162-164.
[2] 谭先凤，张玉秀.孕晚期血清甲胎蛋白与尿酸水平对妊娠期高血压疾病患者妊娠结局的影响[J].海南医学院学报，2016，22（13）：1465-1468.
[3] 周天祥，张修发，翟庆娜，等.同型半胱氨酸、C反应蛋白与妊娠期高血压疾病的关系[J].蚌埠医学院学报，2016， 41（5）：664-665.
[4] 齐东华，葛红岩，罗鑫，等.MicroRNA-126（miR-126）对血管调节的分子机制[J].现代生物医学进展，2014，14（28）：5586-5590.
[5] 乐杰.妇产科学[M].7版.北京：人民卫生出版社，2008：77-79.
[6] Ren LQ，Sun XX，Guan Y，et al. Effects of sevoflurane or propofol combined with remifentanil anesthesia on clinical efficacy and stress response in pregnant women with pregnancy-induced hypertension [J]. Eur Rev Med Pharmacol Sci，2018，22（6）：1825-1829.
[7] 魏继文，吴萍.妊娠期高血压疾病相关影响因素分析[J].重庆医学，2016，45（22）：3078-3080.
[8] 高雪敏，唐飞，钟明，等.妊娠期高血压疾病发病多因素Logictic回归分析[J].淮海医药，2017，35（5）：532-534.
[9] 刘娟，张爱霞.妊娠期高血压疾病住院患者疾病不确定感现状调查及影响因素分析[J].中国实用护理杂志，2017， 33（28）：2181-2185.
[10] 谢雪松.妊娠期高血压疾病发病与产妇妊娠期饮食的相关性研究[J].中国当代医药，2018，25（23）：136-138.
[11] 朱君花，雷侠.高风险子痫前期孕妇妊娠期高血压疾病影响因素的临床研究[J].中国实验诊断学，2017，21（2）：250-253.
[12] 张巧虹，蔡归哲，陈叶敏，等.妊娠期高血压相关影响因素分析[J].中国计划生育学杂志，2016，24（7）：458-460.
[13] 郭龙龙，安冬青，刘伟，等.天香丹干预冠心病秽浊痰阻证病人血浆miR-126表达水平变化研究[J].中西医结合心脑血管病杂志，2017，15（22）：2850-2852.
[14] 陈敏敏，黄晓东.目标导向液体治疗对妇科手术患者血管保护作用及miRNA-126的影响[J].浙江临床医学，2017，19（7）：1347-1348.
[15] 田晓刚，赵林，张春林，等.MicroRNA-126与胃癌患者放化综合治疗效果的关系及其对胃癌SGC-7901细胞的放射增敏作用[J].中国病理生理杂志，2017，21（4）：705-710.
[16] 唐婷，谢治球，赵一俏，等.妊娠期高血压疾病与原发性高血压microRNA-126表达差异[J].现代医院，2017，17（8）：1179-1181.
[17] 唐婷，赵一俏，靳文，等.妊娠期高血压疾病患者血浆microRNA-126的表达及意义[J].广东医学，2017，38（19）： 2972-2974.
[18] 于津，孙峰，郭玉娜，等.妊娠早期同型半胱氨酸和血脂水平对重度子痫前期的预测价值[J].国际妇产科学杂志，2018，45（1）：51-54.
[19] 陈寒，蒋红清.硫酸镁联合硝苯地平治疗妊娠期高血压疾病患者的疗效及对血流动力学、尿蛋白表达水平的影响[J].中国妇幼保健，2017，32（14）：3170-3172.
[20] 中国医师协会高血压专业委员会.妊娠期高血压疾病血压管理中国专家共识[J].中华高血压杂志，2012，20（11）：1023-1027.
[21] 刘真，孙瑜.妊娠期及产褥期静脉血栓栓塞疾病诊治：2015英国皇家妇产科医师学会指南解读[J].中华围产医学杂志，2017，20（12）：841-845.
[22] 柯健，林赴兵，吴小娟.血压干预对妊娠期高血压患者尿微量白蛋白变化与预后关系的回顾性分析[J].中国医药科学，2017，7（21）：239-241，244.
[23] 奚晟黎，张莉.酚妥拉明联合硝苯地平治疗子痫前期临床疗效观察[J].成都医学院学报，2018，13（5）：616-620.
[24] 党玉霞，吴侃倪，王燕萍，等.动态血压监测对妊娠期高血压疾病的预测及治疗指导研究[J].中国医药科学，2018， 8（19）：192-196.